Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | CDK7 | P50613 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | CCNH | P51946 | 1/20 | 0.38 |
| ▸ | POLA1 | P09884 | 1/20 | 0.33 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.33 |
| ▸ | MAP3K6 | O95382 | 1/20 | 0.33 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL788098 | 0.84 | ALDH1A1 (0.52) | ALDH1A1KDM4ERXFP1CDK2PAK1 | |
| SCHEMBL1721311 | 0.82 | ALDH1A1 (0.55) | ALDH1A1KDM4ERXFP1CDK2PAK1 | |
| SCHEMBL29599053 | 0.82 | RXFP1 (0.51) | ALDH1A1KDM4ERXFP1CDK2PAK1 | |
| SCHEMBL7771676 | 0.82 | ALDH1A1 (0.50) | ALDH1A1KDM4ERXFP1CDK2PAK1 | |
| SCHEMBL30556758 | 0.82 | ALDH1A1 (0.50) | ALDH1A1KDM4ERXFP1CDK2PAK1 | |
| SCHEMBL28190667 | 0.79 | ALDH1A1 (0.47) | ALDH1A1KDM4ERXFP1CDK2PAK1 | |
| SCHEMBL6046334 | 0.79 | ALDH1A1 (0.55) | ALDH1A1KDM4ERXFP1CDK2PAK1 | |
| SCHEMBL29400266 | 0.78 | KDM4E (0.46) | ALDH1A1KDM4ERXFP1CDK2PAK1 | |
| SCHEMBL30119558 | 0.78 | ALDH1A1 (0.46) | ALDH1A1KDM4ERXFP1CDK2PAK1 | |
| SCHEMBL28486689 | 0.78 | ALDH1A1 (0.46) | ALDH1A1KDM4ERXFP1CDK2PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233960-A1 | Kinase Inhibitors | DEVGEN NV (BE) | 2009-09-17 | — | — | US | disclosed |
| EP-1934181-A2 | KINASE INHIBITORS | Devgen NV (BE) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007042321-A2 | KINASE INHIBITORS | DEVGEN N.V. (BE) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233960-A1 | Kinase Inhibitors | ROCK1, MAP3K1, MAP3K11 | ALDH1A1 2810/4885KDM4E 4294/4885RXFP1 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.